Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...
i1d
Second Alzheimer’s ‘wonder drug’ blocked for use on NHS due to high costs
NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
'I took Alzheimer's wonderdrug and it changed my life - two symptoms I don't have'
Patient Peter Almond told of his disappointment that donanemab will only be available to those who can pay for a private ...
pharmaphorum4d
FDA puts breakthrough tag on Roche, Lilly Alzheimer’s test
The test could potentially help identify patients eligible for treatment with new amyloid-busting drugs like Eisai and Biogen’s Leqembi (lecanemab ... and expensive PET brain scans or invasive ...
ALZFORUM2d
Lecanemab Tops Other Antibodies at Binding Soluble Aβ Aggregates
Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U.S. marketing approval. What ...
Monthly Prescribing Reference4d
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
Adding 75mg vial size would achieve greatest reduction in waste, representing annual savings of $99 million. HealthDay News — Annual wasteful spending on discarded lecanemab is anticipated to ...
The Daily Telegraph2d
Why thousands of dementia sufferers are being denied the new miracle drug
In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as momentous. Finally, for the first time, a drug had slowed the ...
Pharmabiz6d
Eisai to request reconsideration of initial decision for lecanemab in Australia
Eisai will request a reconsideration of this decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in Australia.